FDA approves Outlook Therapeutics' LYTENAVA, first ophthalmic bevacizumab for neovascular AMD
The FDA approved Outlook Therapeutics' LYTENAVA, the first ophthalmic bevacizumab for neovascular AMD, giving the company a commercial foothold in retinal disease. Outlook Therapeutics also filed an underwriting agreement for 55.56 million shares and warrants at $0.99 per unit to raise fresh capital.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@TU_Crypto_News
Outlook Therapeutics said the FDA approved LYTENAVA, giving the company a key commercial foothold in retinal disease. The drug is the first ophthalmic bevacizumab for neovascular AMD, as Outlook also pushes for broader adoption and fresh capital.
@blckchaindaily
🚨 OUTLOOK THERAPEUTICS $OTLK FILES UNDERWRITING AGREEMENT FOR 55.56M SHARES AND WARRANTS AT $0.99 PER UNIT